Conditions We Treat | Depression & rTMS | Brain Aid Clinics

0466 352 811

Conditions

Your brain. Your specific targets.

TGA-Approved

Medicare Rebate Available

01

Depression

For patients who have not responded to ≥2 antidepressant trials at therapeutic doses. High-frequency rTMS to the left DLPFC is the TGA-approved protocol, eligible for Medicare rebate under MBS items 14216–14220. Neuronavigation improves target precision and may enhance treatment outcomes.

Off-Label

02

Anxiety Disorders

Low-frequency rTMS to the right DLPFC has demonstrated anxiolytic effects across multiple RCTs, with meta-analytic support for reliable symptom reduction. Given high comorbidity rates with depression, treatment is frequently co-administered. Protocol selection is individualised to symptom profile under psychiatrist oversight.

Off-Label

03

Chronic Pain

rTMS targeting the primary motor cortex (M1) and DLPFC has demonstrated analgesic effects across neuropathic pain, fibromyalgia, and central sensitisation disorders. A 2022 RCT found 66.6% of fibromyalgia patients achieved ≥30% pain reduction with DLPFC-targeted rTMS. Protocol is individualised based on pain type and chronicity.

Off-Label

04

Post-COVID Cognitive Symptoms

Prefrontal rTMS has been shown to improve processing speed, working memory, and cognitive endurance in Long COVID presentations. Neuronavigation ensures accurate engagement of the frontal circuits involved in executive function and attentional control, which are frequently disrupted following SARS-CoV-2 infection.

Investigational

05

Migraine

Repetitive TMS protocols targeting the occipital cortex and DLPFC have shown preliminary efficacy for both acute migraine interruption and prophylactic frequency reduction. Evidence from RCTs is encouraging but consensus on optimal protocol — target, frequency, and session number — has not yet been established. Delivered under psychiatrist and neurology-informed oversight.

Investigational

06

Parkinson's Disease

High-frequency rTMS over the motor cortex and supplementary motor area has shown improvements in UPDRS motor scores across multiple RCTs and meta-analyses, with additional benefit for mood and sleep disturbance. Evidence quality remains low-to-moderate per GRADE assessment; treatment is offered as an adjunct to standard neurological management under specialist oversight.

Investigational

07

Complex Regional Pain Syndrome

Motor cortex rTMS has been investigated as a neuromodulatory approach for CRPS-related central sensitisation, with early RCT data showing short-term pain reduction. Evidence remains limited in sample size and follow-up duration. Treatment is considered in patients who have not responded to conventional pain management, under multidisciplinary specialist oversight.

Investigational

08

Trigeminal Neuralgia

Motor cortex stimulation via rTMS targeting the trigeminal representation within M1 has shown analgesic effects in small RCTs and observational studies of refractory orofacial pain. Evidence base is preliminary; treatment is appropriate for patients who have exhausted pharmacological options, under specialist-supervised, neuronavigation-guided protocols.

Investigational

09

Menopause-Related Brain Fog

Hormonal transition disrupts prefrontal circuit function, contributing to cognitive slowing, attentional difficulties, and low mood. Prefrontal rTMS targeting the DLPFC may support working memory and mental clarity in perimenopausal and postmenopausal presentations. Clinical evidence is emerging; treatment is individualised under psychiatrist oversight.

Explore More

⚡

Treatments

How rTMS and tDCS work.

🎯

Why We’re Different

Neuronavigation vs standard rTMS.

📋

Make a Referral

For clinicians — forms and info.

📍

Locations

Gold Coast and Melbourne clinics.